Associated Papers
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S et al.
Antimicrobial Agents and Chemotherapy, 2005
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D et al.
Antiviral Therapy, 2004
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
Resch W et al.
Journal of Virology, 2002
Select a paper to view details